Phosphodiesterase 4 inhibition as a novel treatment for stroke
The incidence of stroke ranks third among the leading causes of mortality worldwide. It has the characteristics of high morbidity, high disability rate and high recurrence rate. The current risk associated with stroke surgery is exceedingly high. It may potentially outweigh the benefits and fail to...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PeerJ Inc.
2025-01-01
|
| Series: | PeerJ |
| Subjects: | |
| Online Access: | https://peerj.com/articles/18905.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832575984975478784 |
|---|---|
| author | Jiahong Zhong Xihui Yu Zhuomiao Lin |
| author_facet | Jiahong Zhong Xihui Yu Zhuomiao Lin |
| author_sort | Jiahong Zhong |
| collection | DOAJ |
| description | The incidence of stroke ranks third among the leading causes of mortality worldwide. It has the characteristics of high morbidity, high disability rate and high recurrence rate. The current risk associated with stroke surgery is exceedingly high. It may potentially outweigh the benefits and fail to ameliorate the cerebral tissue damage following ischemia. Therefore, pharmacological intervention assumes paramount importance. The use of thrombolytic drugs is most common in the treatment of stroke; however, its efficacy is limited due to its time-sensitive nature and propensity for increased bleeding. Over the past few years, the treatment of stroke has witnessed a surge in interest towards neuroprotective drugs that possess the potential to enhance neurological function. The PDE4D gene has been demonstrated to have a positive correlation with the risk of ischemic stroke. Additionally, the utilization of phosphodiesterase 4 inhibitors can enhance synaptic plasticity within the neural circuitry, regulate cellular metabolism, and prevent secondary brain injury caused by impaired blood flow. These mechanisms collectively facilitate the recovery of functional neurons, thereby serving as potential therapeutic interventions. Therefore, the comprehensive investigation of phosphodiesterase 4 as an innovative pharmacological target for stroke injury provides valuable insights into the development of therapeutic interventions in stroke treatment. This review is intended for, but not limited to, pharmacological researchers, drug target researchers, neurologists, neuromedical researchers, and behavioral scientists. |
| format | Article |
| id | doaj-art-35ddcb7fd5bb4084a451ce601193af74 |
| institution | Kabale University |
| issn | 2167-8359 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | PeerJ Inc. |
| record_format | Article |
| series | PeerJ |
| spelling | doaj-art-35ddcb7fd5bb4084a451ce601193af742025-01-31T15:05:08ZengPeerJ Inc.PeerJ2167-83592025-01-0113e1890510.7717/peerj.18905Phosphodiesterase 4 inhibition as a novel treatment for strokeJiahong Zhong0Xihui Yu1Zhuomiao Lin2Department of Clinical Pharmacy, Meizhou People’s Hospital, Meizhou, Guangdong, ChinaDepartment of Pharmacy, The Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, ChinaDepartment of Clinical Pharmacy, Meizhou People’s Hospital, Meizhou, Guangdong, ChinaThe incidence of stroke ranks third among the leading causes of mortality worldwide. It has the characteristics of high morbidity, high disability rate and high recurrence rate. The current risk associated with stroke surgery is exceedingly high. It may potentially outweigh the benefits and fail to ameliorate the cerebral tissue damage following ischemia. Therefore, pharmacological intervention assumes paramount importance. The use of thrombolytic drugs is most common in the treatment of stroke; however, its efficacy is limited due to its time-sensitive nature and propensity for increased bleeding. Over the past few years, the treatment of stroke has witnessed a surge in interest towards neuroprotective drugs that possess the potential to enhance neurological function. The PDE4D gene has been demonstrated to have a positive correlation with the risk of ischemic stroke. Additionally, the utilization of phosphodiesterase 4 inhibitors can enhance synaptic plasticity within the neural circuitry, regulate cellular metabolism, and prevent secondary brain injury caused by impaired blood flow. These mechanisms collectively facilitate the recovery of functional neurons, thereby serving as potential therapeutic interventions. Therefore, the comprehensive investigation of phosphodiesterase 4 as an innovative pharmacological target for stroke injury provides valuable insights into the development of therapeutic interventions in stroke treatment. This review is intended for, but not limited to, pharmacological researchers, drug target researchers, neurologists, neuromedical researchers, and behavioral scientists.https://peerj.com/articles/18905.pdfStrokeBrain injuryPhosphodiesterase 4TargetTherapy |
| spellingShingle | Jiahong Zhong Xihui Yu Zhuomiao Lin Phosphodiesterase 4 inhibition as a novel treatment for stroke PeerJ Stroke Brain injury Phosphodiesterase 4 Target Therapy |
| title | Phosphodiesterase 4 inhibition as a novel treatment for stroke |
| title_full | Phosphodiesterase 4 inhibition as a novel treatment for stroke |
| title_fullStr | Phosphodiesterase 4 inhibition as a novel treatment for stroke |
| title_full_unstemmed | Phosphodiesterase 4 inhibition as a novel treatment for stroke |
| title_short | Phosphodiesterase 4 inhibition as a novel treatment for stroke |
| title_sort | phosphodiesterase 4 inhibition as a novel treatment for stroke |
| topic | Stroke Brain injury Phosphodiesterase 4 Target Therapy |
| url | https://peerj.com/articles/18905.pdf |
| work_keys_str_mv | AT jiahongzhong phosphodiesterase4inhibitionasanoveltreatmentforstroke AT xihuiyu phosphodiesterase4inhibitionasanoveltreatmentforstroke AT zhuomiaolin phosphodiesterase4inhibitionasanoveltreatmentforstroke |